Plexium

Please note: The information displayed on this page might be outdated.
Plexium: Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.
Sector/Industry:
Biotech Company / Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Listing
Private
Website:
Address:
11494 Sorrento Valley Rd.
San Diego, CA 92121
United States

Company Participants at Fall Private Company Showcase 2021

  • Kevin Eastwood, Executive Vice President, Corporate Business Development

Upcoming Company Event Participation